Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Cromoglicate,Bronchodil
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Atlantis Holdings completes acquisition of two brands from Sanofi in Europe & Canada
Details : Lupin has completed the acquisition of two well-known brands, Aarane (sodium cromoglicate) in Germany and Nalcrom (cromoglicic acid) in Canada and the Netherlands, from Sanofi.
Product Name : Aarane
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 06, 2024
Lead Product(s) : Sodium Cromoglicate,Bronchodil
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Sodium Cromoglicate,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : Sodium Cromoglicate,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Respivant Sciences Supports International Rare Disease Day Through Awareness Activities
Details : Respivant also announces 50% enrollment milestone achieved in SCENIC, a Phase 2b Trial of RVT-1601 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 28, 2020
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PUL-042,Sodium Cromoglicate,Salbutamol Sulphate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : WCCT Global
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2015
Lead Product(s) : PUL-042,Sodium Cromoglicate,Salbutamol Sulphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : WCCT Global
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Aradign Corportation | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Cromolyn Detection of Silent Aspiration
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2013
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Aradign Corportation | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2012
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2012
Lead Product(s) : Sodium Cromoglicate,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable